Inside the FDA concerns that sank Hengrui`s PD-1 drug filing
16 Jul 2024 //
FIERCE PHARMA
Elevar And Hengrui Plan Quick Refile After FDA Rejects Cancer Combo
10 Jul 2024 //
FIERCE PHARMA
Merck KGaA Enters Partnership With China`s Hengrui for Up to $1.5 Bln
30 Oct 2023 //
BIOSPACE
Hengrui, Elevar strike $600M marketing deal for liver cancer med
17 Oct 2023 //
FIERCE PHARMA
Strides`s Generic Gadobutrol Receives Approval in the U.S.
17 Nov 2022 //
FDA